SAIC Q2 Earnings Beat Estimates, Stock Falls 7% on Revenue Miss

Science Applications International (SAIC) reported Q2 fiscal 2026 non-GAAP EPS of $3.63, surpassing estimates by 61.3% largely due to lower taxes and legal settlements. However, revenue declined 3% year-over-year to $1.77 billion, missing expectations due to new business award delays and slower on-contract growth, which led to a 6.9% stock decline. Consequently, SAIC lowered its fiscal 2026 revenue and adjusted EBITDA guidance, citing continued top-line pressures, but simultaneously raised its adjusted EPS and free cash flow outlook, reflecting the one-time tax benefits and a revised tax rate assumption.

Analysis

Science Applications International's (SAIC) second-quarter fiscal 2026 results reveal a significant disconnect between reported earnings and underlying operational health. The company posted a non-GAAP EPS of $3.63, a 77% year-over-year increase that beat estimates by over 61%, but this outperformance was artificially inflated by one-time benefits from lower taxes and legal settlements. The market correctly looked past this, focusing on the 3% year-over-year revenue decline to $1.77 billion, which missed consensus estimates and triggered a 6.9% share price drop. This top-line weakness, attributed to delays in new business awards and slower on-contract growth, impacted both the Defence and Intelligence (-2.9%) and Civilian (-2.0%) segments. Management's guidance cut for full-year 2026 revenue and adjusted EBITDA confirms these headwinds are expected to persist. While the company did raise its full-year EPS and free cash flow guidance, the former is again a product of tax benefits, whereas the latter (now exceeding $550 million) and a healthy quarterly book-to-bill ratio of 1.5 stand as the few genuine operational bright spots. However, the trailing 12-month book-to-bill ratio of 1.0 suggests a longer-term trend of merely replacing, rather than growing, the revenue pipeline.

Key Decisions for Investors

• Investors should view the significant Q2 EPS beat and upwardly revised full-year guidance with caution, as they are primarily driven by non-recurring tax and legal benefits, not by improved operational performance.
• The primary focus should be on the persistent top-line weakness, evidenced by the 3% revenue decline and the substantial cut in fiscal 2026 revenue guidance, which signals ongoing delays in contract awards and slower growth conversion.
• While the deteriorating growth outlook is a major concern, the strong free cash flow forecast (exceeding $550 million) and aggressive capital return program ($110 million in Q2 buybacks) may provide a degree of valuation support for the stock.
• Monitor the book-to-bill ratio in subsequent quarters to gauge whether the strong 1.5 ratio in Q2 marks a turning point in pipeline growth or was an anomaly, given the trailing 12-month ratio remains a stagnant 1.0.